Premium
Characterization of six cell lines established from human pancreatic adenocarcinomas
Author(s) -
Kato Masayuki,
Shimada Yutaka,
Tanaka Hisashi,
Hosotani Ryo,
Ohshio Gakuji,
Ishizaki Kanji,
Imamura Masayuki
Publication year - 1999
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/(sici)1097-0142(19990215)85:4<832::aid-cncr10>3.0.co;2-7
Subject(s) - medicine , cell culture , adenocarcinoma , cancer research , pathology , cancer , genetics , biology
BACKGROUND Six human pancreatic carcinoma cell lines, designated as KMP‐1 to KMP‐6, were established and maintained in vitro for > 3 years. All were derived from pancreatic ductal adenocarcinomas. The six cell lines originated from either primary pancreatic tumors, metastatic liver tumors, or metastases to lymph nodes. METHODS Each cell line was characterized by its morphology, doubling time, colony forming efficiency (CFE) on plastic dishes, tumorigenicity in nude mice, chromosomal analysis, and the amount of tumor markers secreted into the culture medium. Furthermore, mutations in the K‐ ras , p53, and p16/INK4a genes were analyzed. RESULTS All cell lines grew as an adhering monolayer and were cultured in medium supplemented with 2% fetal bovine serum. The doubling time ranged from 16‐70 hours, and the CFE ranged from 0.1‐11%. Subcutaneous transplantation of these carcinoma cells into nude mice resulted in the formation of tumors. Chromosomal analysis showed that the modal numbers ranged from 43‐124, and each karyotype was unique. Each cell line secreted detectable amounts of squamous cell carcinoma antigen, carcinoembryonic antigen, carbohydrate antigen 19‐9, Dupan‐II, and cytokeratin 19 fragment, respectively. Genetic alterations of the K‐ ras , p53, and p16 genes were detected in six, three, and five, respectively, of the six cell lines. CONCLUSIONS The authors believe that these newly established pancreatic carcinoma cell lines will contribute to wide ranging studies regarding pancreatic carcinoma progression. Cancer 1999;85:832–40. © 1999 American Cancer Society.